US biopharma company Incyte bags Opzelura FDA approval for vitiligo
Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US Food and Drug Administration (FDA) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients, aged 12 and older. Opzelura is a cream formulation of ruxolitinib, which selectively inhibits JAK1/JAK2. Opzelura FDA approval for vitiligo […]